Holistic Extractables and Leachables Program: Evaluations of Prefilled Syringe Systems for Biotechnology Products

References

1. 1.↵
   1. Jenke D. R.

   Extractables and Leachables Considerations for Prefilled Syringes. Expert Opin. Drug Delivery 2014, 11 (10), 1591–1600.

   OpenUrl
2. 2.↵
   1. Nashed-Samuel Y.,
   2. Liu D.,
   3. Fujimori K.,
   4. Perez L.,
   5. Lee H.

   Extractable and Leachable Implications on Biological Products in Prefilled Syringes. Am. Pharm. Rev. 2011, 14 (1),74–80.

   OpenUrl
3. 3.↵
   1. Harrison B.,
   2. Rios M.

   Big Shot: Developments in Pre-Filled Syringes. Pharm. Technol. 2007, 31 (3), 50–56.

   OpenUrl
4. 4.↵
   1. Walsh G.

   Biopharmaceutical Benchmarks 2006. Nat. Biotechnol. 2006, 24 (7), 769–776.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Li K.,
   2. Rogers G.,
   3. Nashed-Samuel Y.,
   4. Lee H.,
   5. Mire-Sluis A.,
   6. Cherney B.,
   7. Forster R.,
   8. Yeh P.,
   9. Markovic I.

   Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products. PDA J. Pharm. Sci. Technol. 2015, 69 (5), 590–619.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Dorival-García N.,
   2. Larsson I.,
   3. Bones J.

   Non-Volatile Extractable Analysis of Prefilled Syringes for Parenteral Administration of Drug Products. J. Pharm. Biomed. Anal. 2017, 142, 337–342.

   OpenUrl
7. 7.↵
   1. Sacha G.,
   2. Rogers J. A.,
   3. Miller R. L.

   Pre-Filled Syringes: A Review of the History, Manufacturing and Challenges. Pharm. Dev. Technol. 2015, 20 (1), 1–11.

   OpenUrl
8. 8.↵
   1. Petersen C.,
   2. Zeiss B.

   Pre-Fillable Syringes for the Biotechnological Requirements of the Present and Future. International Pharmaceutical Industry 2016, 8 (2), 32–39.

   OpenUrl
9. 9.↵
   1. Waxman L.,
   2. Vilivalam V. D.

   A Comparison of Protein Stability in Prefillable Syringes Made of Glass and Plastic. PDA J. Pharm. Sci. Technol. 2017, 71 (6), 462–477.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Liu W.,
    2. Swift R.,
    3. Torraca G.,
    4. Nashed-Samuel Y.,
    5. Wen Z.-Q.,
    6. Jiang Y.,
    7. Vance A.,
    8. Mire-Sluis A.,
    9. Freund E.,
    10. Davis J.,
    11. Narhi L.

    Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-Filled Syringes. PDA J. Pharm. Sci. Technol 2010, 64 (1), 11–19.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Nashed-Samuel Y.,
    2. Torraca G.,
    3. Liu D.,
    4. Fujimori K.,
    5. Zhang Z.,
    6. Wen Z.-Q.,
    7. Lee H.

    Identification of an Extraneous Black Particle in a Glass Syringe, Extractables/Leachables Case Study. PDA J. Pharm. Sci. Technol. 2010, 64 (3), 242–248.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Liu D.,
    2. Nashed-Samuel Y.,
    3. Bondarenko P. V.,
    4. Brems D. N.,
    5. Ren D.

    Interactions between Therapeutic Proteins and Acrylic Acid Leachable. PDA J. Pharm. Sci. Technol. 2012, 66 (1), 12–19.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    U.S. Food and Drug Administration, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 1997.
14. 14.↵
    1. Markovic I.

    Evaluation of Safety and Quality Impact of Extractable and Leachable Substances in Therapeutic Biologic Protein Products: A Risk-Based Perspective. Expert Opin. Drug Saf. 2007, 6 (5), 487–491.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    International Conference for Harmonisation, Quality Guideline Q3D(R1): Guideline for Elemental Impurities. ICH: Geneva, 2019.
16. 16.↵
    International Conference for Harmonisation. Quality Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH: Geneva, 2017.
17. 17.↵
    1. Wakankar A. A.,
    2. Wang Y. J.,
    3. Canova-Davis E.,
    4. Ma S.,
    5. Schmalzing D.,
    6. Grieco J.,
    7. Milby T.,
    8. Reynolds T.,
    9. Mazzarella K.,
    10. Hoff E.,
    11. Gomez S.,
    12. Martin-Moe S.

    On Developing a Process for Conducting Extractable–Leachable Assessment of Components Used for Storage of Biopharmaceuticals. J. Pharm. Sci. 2010, 99 (5), 2209–2218.

    OpenUrlPubMed
18. 18.↵
    1. Singh S. K.

    Impact of Product-Related Factors on Immunogenicity of Biotherapeutics. J. Pharm. Sci. 2011, 100 (2), 354–387.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Jiang Y.,
    2. Nashed-Samuel Y.,
    3. Li C.,
    4. Liu W.,
    5. Pollastrini J.,
    6. Mallard D.,
    7. Wen Z.-Q.,
    8. Fujimori K.,
    9. Pallitto M.,
    10. Donahue L.,
    11. Chu G.,
    12. Torraca G.,
    13. Vance A.,
    14. Mire-Sluis T.,
    15. Freund E.,
    16. Davis J.,
    17. Narhi L.

    Tungsten-Induced Protein Aggregation II: Solution Behavior. J. Pharm. Sci 2009, 98 (12), 4695–4710.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Bee J. S.,
    2. Nelson S. A.,
    3. Freund E.,
    4. Carpenter J. F.,
    5. Randolph T. W.

    Precipitation of a Monoclonal Antibody by Soluble Tungsten. J. Pharm. Sci. 2009, 98 (9), 3290–3301.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Jones L. S.,
    2. Kaufmann A.,
    3. Middaugh C. R.

    Silicone Oil Induced Aggregation of Proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Thirumangalathu R.,
    2. Krishnan S.,
    3. Ricci M. S.,
    4. Brems D. N.,
    5. Randolph T. W.,
    6. Carpenter J. F.

    Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 2009, 98 (9), 3167–3181.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Seidl A.,
    2. Hainzl O.,
    3. Richter M.,
    4. Fischer R.,
    5. Böhm S.,
    6. Deutel B.,
    7. Hartinger M.,
    8. Windisch J.,
    9. Casadevall N.,
    10. London G. M.,
    11. Macdougall I.

    Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa during Primary Packaging as a Cause of Immunogenicity. Pharm. Res. 2012, 29 (6), 1454–1467.

    OpenUrlCrossRefPubMed
24. 24.↵
    International Conference for Harmonisation. Quality Guideline Q3C(R6): Impurities: Guideline for Residual Solvents. ICH: Geneva, 2016.
25. 25.↵
    1. Uglea C. V.

    Oligomer Technology and Applications; CRC Press: Boca Raton, 1998; pp 278.
26. 26.↵
    1. Rubic-Schneider T.,
    2. Kuwana M.,
    3. Christen B.,
    4. Aßenmacher M.,
    5. Hainzl O.,
    6. Zimmermann F.,
    7. Fischer R.,
    8. Koppenburg V.,
    9. Chibout S.-D.,
    10. Wright T. M.,
    11. Seidl A.,
    12. Kammüller M.

    T-Cell Assays Confirm Immunogenicity of Tungsten-Induced Erythropoietin Aggregates Associated with Pure Red Cell Aplasia. Blood Adv. 2017, 1 (6), 367–379.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Marghitoiu L.,
    2. Liu J.,
    3. Lee H.,
    4. Perez L.,
    5. Fujimori K.,
    6. Ronk M.,
    7. Hammond M. R.,
    8. Nunn H.,
    9. Lower A.,
    10. Rogers G.,
    11. Nashed-Samuel Y.

    Extractables Analysis of Single-Use Flexible Plastic Biocontainers. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 49–58.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Langer E.,
    2. Rader R. A.

    Top Trends in Biopharmaceutical Manufacturing, 2017. Pharm. Technol. 2017, 41 (9), 58–60.

    OpenUrl
29. 29.↵
    1. Gao Y.,
    2. Allison N.

    Extractables and Leachables Issues with the Application of Single Use Technology in the Biopharmaceutical Industry. J. Chem. Technol. Biotechnol. 2016, 91 (2), 289–295.

    OpenUrl
30. 30.↵
    1. Shukla A. A.,
    2. Gottschalk U.

    Single-Use Disposable Technologies for Biopharmaceutical Manufacturing. Trends Biotechnol. 2013, 31 (3), 147–154.

    OpenUrlCrossRefPubMed